Article
Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
European review for medical and pharmacological sciences - 1 Nov 2015
Di Francia R, De Lucia L, Di Paolo M, Di Martino S, Del Pup L, De Monaco A, Lleshi A, Berretta M
Abstract excerpt
OBJECTIVE: Both Fluoropyrimidine and Oxaliplatin (FluOx) are the most common anticancer drugs used to treat colorectal, ovarian, and gastrointestinal cancers. Nevertheless, the efficacy of FluOx-based therapy is often compromised by the severe risk of neurotoxicity, cardiotoxicity, and gastrointestinal toxicity. Stratification of patients for their individual response to drugs is a promising approach for cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.